Creo Medical Group (LON:CREO) Reaches New 52-Week Low – Here’s Why

Creo Medical Group PLC (LON:CREO) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 15.50 ($0.20) and last traded at GBX 15.95 ($0.20), with a volume of 449749 shares traded. The stock had previously closed at GBX 16.13 ($0.20).

Creo Medical Group Price Performance

The company has a market capitalization of £57.88 million, a PE ratio of -266.67 and a beta of 0.86. The company has a quick ratio of 2.19, a current ratio of 3.24 and a debt-to-equity ratio of 29.96. The firm’s 50-day moving average is GBX 21.19 and its 200-day moving average is GBX 28.37.

Insider Activity

In other news, insider Richard John Rees bought 98,000 shares of the business’s stock in a transaction dated Thursday, October 24th. The shares were purchased at an average price of GBX 20 ($0.25) per share, for a total transaction of £19,600 ($24,847.87). Also, insider Kevin Crofton bought 2,916,666 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was purchased at an average cost of GBX 24 ($0.30) per share, for a total transaction of £699,999.84 ($887,423.73). 22.43% of the stock is owned by corporate insiders.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.